Skip to content

First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with Egfr Activating Mutations

The medicines shown here belong to the Oncology Support category and are used for managing First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with Egfr Activating Mutations. Products containing Erlotinib feature in this group.

Tarceva

Erlotinib

100mg

Blocks epidermal growth factor receptor tyrosine kinase to stop cancer cells from growing and spreading in non-small cell lung cancer and pancreatic cancer.

From$16.27/ tabletView

Review product labelling and speak with a healthcare professional before treatment decisions.